SNT 2.22% 4.4¢ syntara limited

Ann: Final Set of Interim Data from PXS-5505 in Myelofibrosis, page-7

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 7,135 Posts.
    lightbulb Created with Sketch. 546
    If you look back for the last 10 years, Pharmaxis has always been able to have this kind of "positive" media coverage and articles, however their expensive, time consuming trail results only sank the share price more than 80%.
    seems their pipelines are at most "interesting" to the big pharmas, but not good enough to land any deals (since BI thrown back their PXS - 4728 in 2019).
    I am sure if Gary Philips was truly "extremely excited" about those results, or just to talk it up for another CR for the endless such trails in the next 5 years.
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.